

Life After CIDP



Betty Soliven, MD

Professor

Department of Neurology

The University of Chicago


Patients' reactions after dx of CIDP



Is there any
treatment for this
condition?

What is CIDP?

- * Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disorder characterized by inflammation of peripheral nerves and nerve roots resulting in destruction of myelin sheath (fatty protective covering).



Medgadget

CIDP- cont'd

- * Incidence (new cases): 0.7 -1.6/100,000 per yr; prevalence: 0.8-8.9/100,000
- * Men > women (2:1)
- * Can affect all ages; average age of onset ~50 y/o
- * It can be progressive (14.5%), relapsing-remitting (71%), or monophasic (one bout lasting 1-3 yrs) (14.5%) (Mahdi-Rogers, 2010).
- * Other studies: relapsing form (20-35%)(Vallat 2010); monophasic in 53%, relapsing in 47% (Barohn 1989)

Historical Perspectives

- * 1874: The first case report of “recurrent neuritis” (Eichhorst H. Virchows Archiv 1874).
- * 1921: Association of recurrent neuritis with nerve hypertrophy was reported (Nattrass FJ . J Neurol Psychopathol. 1921)
- * 1958: “Recurrent, steroid responsive neuropathy” was described in 2 patients and clinical features reviewed in additional 9 patients (Austin JH. Brain 1958)
- * 1975: The term “chronic inflammatory demyelinating polyradiculoneuropathy” was coined, analyzed clinical/ pathological data from 53 patients (Dyck PJ, et al. Mayo Clin Proc 1975).
- * 1982: first report of plasmapheresis in CIDP (Tindall RS. Prog. Clin. Biol. Res 1882)
- * 1985: The first use of IV immunoglobulin (IVIg) in CIDP (Vermulen M, et al, J Neurol. Sci 1985)


Clinical Features of CIDP

- * Clinical features:
 - * Symmetric weakness of proximal and distal muscles progressing over 2 months
 - * Varying degrees of tingling and numbness
 - * Reflexes reduced or absent
 - * Cranial nerves may be involved (e.g. facial weakness).
- * Other symptoms (+/-): fatigue, neuropathic pain, tremors, restless leg syndrome, mild autonomic dysfunction (GI & GU)





W/u for CIDP

- * Laboratory tests
 - * Looking for mimics
 - * Antibodies against PNS (ganglioside Ab, anti-MAG etc)
- * Nerve conduction testing: very slow conduction velocities
- * Spinal tap: high protein
- * Sometimes nerve biopsy is done to exclude other inflammatory neuropathy (sarcoidosis, vasculitis)
- * Lumbar spine MRI: may show enlarged nerve roots

NCS/EMG



Demyelinating features on NC studies



Pytel P, et al. Acta Neuropathol. 2003

What causes CIDP?

- * It is an autoimmune disorder whereby the immune system attacks the myelin sheath, but **the triggering factor is unclear.**
- * The autoantigen is unknown in the majority of cases.
- * Antibodies to nerve components such as gangliosides, P0 and paranodal proteins reported in a small percentage of patients
- * Different antigens and immunopathogenesis could be involved in different CIDP subtypes.

Animal models of CIDP

- * Chronic EAN

- * Immunization with PNS myelin + low dose CsA caused a relapsing form of EAN in Lewis rats, whereas high dose CsA attenuated the disease (McCombe PA, et al. J. Neuroimmunol. 1990).

- * Spontaneous autoimmune polyneuropathy


- * B7-2 knockout nonobese diabetic (NOD) mice (Salomon et al., 2001; Kim et al., 2008)
- * NOD.Aire^{GW/+} (Su et al., 2008)
- * Others

Do I really have CIDP?

- * In a retrospective study, about half of the 59 patients incorrectly carry the diagnosis of CIDP if reanalyzed according to the EFNS/PNS criteria.
- * Reasons for misdiagnosis:
 - * Overreliance on the subjective improvement with treatments
 - * Liberal interpretation of demyelination based on nerve conduction studies
 - * Overstated importance of borderline or mildly elevated protein

Misdiagnosis

Figure Alternative diagnosis for patients without chronic inflammatory demyelinating polyneuropathy



How is CIDP treated?

- * **Steroids**
- * **Intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin****
 - * **Some patients require maintenance IVIg**
 - * **Hizentra (subcutaneous) approved in 2018**
- * **Plasma exchange: remove antibodies or small molecules****
- * **Other medications that suppress the immune system**
 - * **Mycophenolate, azathioprine, methotrexate, cyclosporine, tacrolimus**
- * **Cyclophosphamide or Rituximab (to deplete B lymphocytes) in refractory cases.**
- * **Hematopoietic stem cell transplant?**

** proven by clinical trial


Steroids

- * Suppress multiple genes that are activated in autoimmune diseases
- * Advantage: low cost
- * Potential side effects: diabetes, high BP, wt gain, insomnia, osteoporosis, gastritis, cataract, glaucoma etc
- * No difference between daily Pred vs pulse high dose oral dexamethasone in terms of outcome
- * Some centers use i.v. methyprednisolone (weekly)

Immunoglobulins (IV or SC)

- * Acts on complement system, Fc receptors, compete with pathogenic antibodies
- * Transient side effects in 49% (HA, flu-like Sxs)
- * More serious side effects: aseptic meningitis, renal impairment, blood clots
- * No consensus re optimal maintenance dose and frequency (0.4 to 1.2 g/kg every 2-6 wks).
- * Data from the ICE trial of IVIg and the PATH trial of SCIg show that 58% and 37% of patients, respectively, did not relapse during treatment with placebo (means dose can be reduced or d/c in some pts after 6 mo)
- * Psychological dependence on IVIg

Proposed mechanism of action of IVIG



Why am I not responding to IVIg or steroids?


- * Misdiagnosis- You don't have CIDP
- * Some CIDP variants do not respond as well as others to IVIg
- * CIDP illness associated with other medical conditions
 - * Sjogren's and other rheumatologic conditions
 - * Sarcoidosis
 - * Hepatitis (B or C)
 - * HIV
 - * CIDP + diabetes
- * Severe loss of axons/nerve fibers

CIDP variants

- * Lewis Sumner syndrome- also asymmetrical affecting sensory and motor function; responds to the usual treatment for CIDP
- * Pure motor CIDP- IVIg better than steroids; some deteriorates on steroids
- * Sensory-predominant CIDP
- * Distal acquired demyelinating symmetric neuropathy (DADS):
 - * with IgM paraprotein- tends to be resistant to usual treatments; 50% with anti-MAG Ab
 - * w/o IgM paraprotein- responds to usual treatments

CIDP variants- cont'd

- * CIDP variants associated with antibodies against nodal or paranodal protein (neurofascins, contactin)
- * Some patients have significant tremors; others with gait imbalance
- * Some variants respond better to rituximab than IVIg



Other Chronic autoimmune neuropathies (CIDP mimics)

- * Multifocal motor neuropathy- asymmetric weakness usually starting in the hands; responds very well to IVIg but may get worse with steroids
 - * Associated with IgM anti-GM1 antibody
- * Anti-myelin associated glycoprotein (MAG) neuropathy
 - * presents with numbness, tingling and gait imbalance; some with weakness
 - * Tends to be resistant to usual treatments
- * POEMS- polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes
 - * Usually high VEGF; or sclerotic bone lesion
 - * Respond to lenalidomide (revlimid)

Living with CIDP

- * Early treatment is important to keep the condition under control
- * Response to treatments and the course of illness vary between patients
- * CIDP patients often experience pain, fatigue and reduced quality of life
- * Physical therapy, occupational therapy and assistive devices (AFOs, cane, walker)
- * Frequent foot inspection for pressure ulcers or injuries
- * Symptomatic treatment for tingling and pain
 - * Gabapentin (neurontin), pregabalin (lyrica): act on a subtype of calcium channel that mediates pain
 - * Duloxetine (cymbalta), nortriptyline, venlafaxine (effexor): increase the threshold for pain perception

Cannabinoids

- * No controlled studies in CIDP
- * May help neuropathic pain
- * CBD and THC have some inhibitory effect on T lymphocytes or B lymphocyte function, but clinical data in autoimmune conditions such as multiple sclerosis are inconsistent.
- * Side effects: increased heart rate, agitation, nausea, seizures, kidney injury, hallucinations, psychosis etc.

Practical tips

- * Blood test monitoring if patients are on immunosuppressants to detect side effects early (diabetes, bone marrow suppression, renal dysfunction)
- * Those on steroids need to be on medications to protect against gastritis or ulcer, take calcium and Vit D supplements to minimize osteoporosis, and have bone density measurements as well as regular eye check up for cataracts, glaucoma
- * While on steroids, decrease carbs in the diet. Significant wt gain can impact mobility.

Practical tips-continued

- * Exercise- Keep active as much as possible; focus on aerobics and flexibility; do passive range of motion or stretching exercises (particularly those wearing braces)
- * Diet- No controlled studies. But some recommend diet rich in antioxidants, anti-inflammatory (avoid saturated fats) and low in carbs (if on steroids).
- * There are two aspects to any disease: the illness itself and the coping mechanism. Do not hesitate to seek help if you are depressed.
- * In general life expectancy is good and comparable to healthy controls. However, complications from treatments may occur.

How about vaccination?

- * General rule- No live virus vaccine while on steroids or immunosuppressants
 - * For shingles vaccine, use shingrix (recombinant viral protein) instead of zovirax (live attenuated virus)
 - * Good resource: CDC website to check if a vaccine contains live virus or not.
- * Flu vaccines are considered safe in recent studies (after 1976). However, in rare pts who develop GBS within 6 wks after prev flu vaccines, it may be prudent to withhold future flu vaccination

How about vaccination?

- * About 1/100,000 patients who received vaccination against H1N1 influenza A in 1976 developed GBS
- * Risk of developing GBS after seasonal flu vaccine and H1N1 vaccination campaign in 2009 is estimated at 1.6 cases per million vaccinations
- * Influenza vaccination might reduce the chance of developing GBS after influenza infection
- * Recurrence of GBS after vaccination unlikely
- * Vaccination to be avoided in vaccination related GBS and GBS in the 3 month period before the vaccination

Prognosis

- * Long term prognosis is generally favorable (5 yr follow-up) (Kuwabara et al., 2006)
 - * 26% in complete remission (w/ normal nerve conduction studies), while 61% in partial remission (able to walk with or w/o immune treatments)
 - * 39% still required immune treatments
 - * 13% had severe disability (unable to walk)
- * In a 5 year follow up study (Gorson KC, et al, 2010):
 - * 11% classified as cured
 - * 44% stable/active on therapy
 - * 18% were untreated or refractory to treatment
 - * Overall 75% of treated patients were stable off treatment or treatment responsive

Prognosis- cont'd

- * Poor prognostic factors:
 - * Older patients
 - * Rapidly progressive course
 - * CNS involvement
 - * Severe secondary axonal involvement on EMG
 - * Axons regenerate but very slowly
 - * Remyelination and axonal regeneration may also be impeded by ongoing inflammation

Clinical trials

- * Recent oral fingolimod trial failed
- * SC Immunoglobulin (IgPro20) worked
- * Other SC immunoglobulin Phase III study to start soon
- * Potential trials using therapies to block recycling via increased FcRn binding, which leads to fast depletion of the autoimmune disease-causing IgG autoantibodies

Treatment utilization over the 2 yr follow-up

- * In a retrospective study based on adjudicated claims, 83.2% of pts (from 7/1/2010 to 6/30/2014) initiated therapy in a median of 52 days.
 - * 57.4% had steroids only (costs ~\$7,900)
 - * 27.5% had IVIg only (costs ~\$165,000)
 - * 8.2% had combination of IVIg and steroids
 - * 4% had plasma exchange
 - * Others: azathioprine, mycophenolate
- * Frequent use of opioids (60.6%), anti-convulsants (45.7%) and anti-depressants (44.2%).

Conclusions

- * CIDP is a common form of treatable neuropathy with a spectrum of clinical phenotypes.
- * Probably heterogeneous disease from the immunopathogenic standpoint
- * Correct diagnosis is essential. Incorrect diagnosis will result in treatments which will be costly and/or subject the patient to serious side effects of pharmacotherapy.
- * Most of CIDP patients respond favorably to treatment
- * Pharmacogenetic studies may provide insight regarding immunotherapy in individual patients
- * If untreated, it may cause severe disability and shorten the lifespan.